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Objective: The present study aimed to evaluate the influence of the relative composition of trace elements and
vitamins in physicochemical stability of neonatal parenteral nutrition.
Material and methods: Three formulations for neonatal administration were selected; the main variable was the
presence of trace elements and vitamins. The analyses where carried out immediately after preparation and at 24 h,
48 h, 72 h and 7 days after preparation. Three methods were selected to determine globule size: light obscuration,
dynamic light scattering and optical microscopy. Complementary evaluation including visual inspection,
determination of pH and osmolarity, peroxide levels and measurements of zeta potential were also performed.
Results: There was an observable alteration in color and phase separation in the PN stored at 25°C and 40°C.
Neither globule size pattern, nor any other physicochemical characteristic evaluated appeared to be considerably
altered in any of the analyzed formulations even after 7 days of storage at 5°C. Globule size in all the PN studied
was consistent with the established limit, below 500 nm by DLS measurement, and PFAT5 was below 0.05% under
all storage temperatures.
Conclusion: Concomitant presence of trace elements and vitamins in the same neonatal formulation did not alter
the evaluated aspects of stability.
Keywords: Total nutrient admixtures, Stability, Lipid globules, Dynamic light scattering, Light obscuration, Optical
microscopyBackground
Neonates are a special target in parenteral nutrition
(PN) practice. Their survival is usually related to its use,
particularly if we consider preterm neonates, born before
37 weeks of pregnancy. These patients need differing
amounts of nutrients when compared to older children
or adults. The concentration of nutrients and factors
such as pH directly impacts the physicochemical proper-
ties of PN preparations. Pediatric amino acid solutions* Correspondence: valeria@pharma.ufrj.br
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reproduction in any medium, provided the orusually include cysteine hydrochloride, which causes
these formulations to be more acidic than adult ones.
These neonatal PN formulations present a high propor-
tion of carbohydrates, amino acids and lipids, as neo-
nates have higher energy requirements than older
children or adults [1–3]. It is important to consider that
the final preparation has a reduced volume when com-
pared to formulations for older children or adults [2],
therefore interactions will be increased between sub-
stances in PN formulations.
All nutrients necessary to ensure neonatal survival
must be contained in a neonatal total PN preparation
(TPN). However, incompatibilities may occur when mix-
ing vitamin and trace elements in the same preparation.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tered on alternate days or using two separate bags of
TPN. However, administration of indispensable nutrients
on alternate days may not have as favorable an outcome
as normal nutrition that is provided in a balanced and
stable formula. It has been widely recommended that
vitamins and trace elements should be administered on
the same day, however using two separate bags and in-
fusing each for twelve hours, so as to avoid interactions
between these nutrients [4,5]. The same procedure is ap-
plied to calcium and phosphorus (Ca/P) neonate supple-
mentation, which must be administrated at a ratio
higher than 1.7 Ca:1.0 P, as previously shown by our
group [3]. The infusion of two bags daily will increase
the number of manipulations necessary when adminis-
tering a set of TPN thus increasing contamination risks
[4,6,7]. Moreover, most services do not compound trace
elements and vitamins in the same bag since trace ele-
ments could promote oxidation of vitamins. Ascorbic
acid is the least stable vitamin and subsequently is oxi-
dized in the presence of oxygen in a reaction catalyzed
by copper ions [8]. This reaction leads to two acidic pro-
ducts: threonic acid and oxalic acid, the latter is consid-
erably stronger and could acidify the preparation thus
compromising the stability of the emulsion [3,9].
The pH is an important parameter to be controlled
when considering lipid stability of a TPN since the pres-
ence of positive charges may disturb the efficiency of the
emulsifier agent, egg lecithin. A pH value below 5.0 can
destabilize the emulsion [9]. Furthermore, trace elements
are frequently positively charged and, thus, may alter the
distribution pattern of lipid globules when added to a
TPN [4,5,9,10].
There are many fundamental aspects to consider
regarding the safety of total parenteral nutrition admix-
tures (TPN) for neonatal use, two of them, sterility and
homogeneity of the emulsion, have received special at-
tention in recent years [7,11–14]. Lack of sterility can
lead to lethal occurrences. The recommendations for
manufacturing sterile products are described in the last
edition of the United States Pharmacopeia (USP) [14].
Homogeneity is also a fundamental aspect which is ne-
cessary to avoid harmful characteristics in the emulsion.
In a stable injectable emulsion, individual lipid particles
must be between 0.25 to 0.5 μm in size to maintain a
homogenous dispersion in the water solution and be
consistent with the chylomicrons size in order to be
assimilated by the body [15]. An increase in lipid particle
size favors coalescence and creaming which makes the
dispersion unstable and potentially dangerous for the pa-
tient [11,16]. The USP suggests two methods to measure
injectable lipid emulsion (ILE) stability, which include
the globule size distribution and the percentage of fat
globules (PFAT). To be considered stable and safe, anILE must meet the USP requirements where mean drop-
let size cannot exceed 500 nm and PFAT must be less
than 0.05 % for PFAT of 5 μm (PFAT5) [14]. Many stud-
ies have demonstrated that TPN is stable when these
parameters are met [12,16–18]. Some authors have also
described optical microscopy as an alternative method
for characterizing or evaluating physical stability of the
PN. These methods use direct observation to determine
the size distribution of the internal phase – lipid glo-
bules [3,19]. Peroxide levels, zeta potential and visual
aspects are additional parameters that can be evaluated
when characterizing the physicochemical properties of
TPN [16,20]. Nevertheless, until now no official com-
pendium or harmonized methodology has been estab-
lished to evaluate TPN stability.
In the present study, the effect of added trace elements
and vitamins on the physicochemical stability of neo-
natal TPN formulas was studied. Formulas that con-
tained both of these nutrients were compared to TPN
that contained only one of these two components. The
impact of these nutrients on the physicochemical stabil-
ity of neonatal TPN was evaluated by measurement of
peroxide levels, pH, zeta potential, osmolarity, sterility
and visual aspects at different storage temperatures.
Additionally, size distribution of lipid globules was deter-
mined by optical microscopy (OM) and the dynamic
light scattering method (DLS) [1,21] and the percentage
of different sized lipid globules, expressed as PFATx, was
determined by light obscuration [12].
Material and methods
Composition of the admixtures
Nutrients used in the preparation of the TPN formula-
tions were obtained from laboratories registered in Brazil’s
National Health Department. The raw materials had certi-
ficates of analysis provided by the suppliers.
The following materials were used for preparation and
preservation of the formulations: 10% pediatric amino
acid solution with taurine (PrimeneW) (lots 0400105 and
0401009), 50% glucose solution (lots PR41LO and
PR42W9) and water for injection (WFI) (lots PB00X3,
PB00X4 and PB01A) from Baxter Laboratories, Brazil;
20% MCT/LCT lipid emulsion (LipofundinW) (lot
4222A182) and zinc acetate (lot 2513001–2) from
BBraun Laboratories, Brazil; 20% sodium chloride (lots
0418957, 0419152, and 0419853), magnesium sulphate
(lots 0418736, 0418735 and 0520199 ) and trace-
elements (Ped-elementW) (lots 0418267 and 0419440)
from Darrow Laboratories, Brazil; calcium gluconate
(lots 733/02, 736/01, 727/01 and 730/01) from Halex-
Istar Laboratories, Brazil; organic phosphate (PhocytanW)
(lot 449360-B), from Aguettant, France, vitamin complex
(MVI 12 opoplexW) (lot 002/04) from ICN Pharmaceut-
ical, Brazil.
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NP3, containing vitamins and trace elements were pre-
pared (Table 1). The composition of these formulations
was designed based on the worldwide recommenda-
tions for nutrients administered by PN in pediatric
clinical practice [2,11]. The NP3 formulation, contain-
ing both nutrients, is not routinely prepared in the
pharmaceutical practice of compounding TPN. This
formulation was designed as a model for the present
study, to test the influence of the concomitant pres-
ence of these nutrients on the final stability of the














































Final volume q.s. 100 mLThe lipid emulsion used in the formulations, contain-
ing 20% MCT/LCT, is the most prescribed to neonates
in clinical practice of TPN in Brazil and has good stabil-
ity [1].
It is also interesting to note that the three formula-
tions contained Ca and P, in standard doses, within the
same bag.
Preparation of TPN
Formulations were prepared aseptically, following inter-
national recommendations, under a laminar airflow
hood in a clean room [7,11,14,22,23] and disposed inton
tock solution)
NP2 NP3
mL) 30 mg/mL(30 mL) 30 mg/mL(30 mL)
.3 mL) 80 mg/mL(17.3 mL) 80 mg/mL(17.3 mL)
mL) 30 mg/mL (15 mL) 30 mg/mL(15 mL)
.2 mL) 235 mg/mL(1.2 mL) 235 mg/mL(1.2 mL)
L) 3 mg/mL(3 mL) 3 mg/mL(3 mL)
5 mL) 1.2 mg/mL(0.5 mL) 1.2 mg/mL(0.5 mL)
.25 mL) 0.15 mg/mL(0.25 mL) 0.15 mg/mL(0.25 mL)
0.2 μg/mL 0.2 μg/mL
0.002 μg/mL 0.002 μg/mL
0.02 μg/mL 0.02 μg/mL
0.5 μg/mL 0.5 μg/mL
(0.2 mL) (0.2 mL)
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Ltda, São Paulo, Brazil). Transfers were performed by
the lateral injector using sterile syringes. To attenuate
possible incompatibilities, solutions were added to the
admixtures according to the recommendations of
ASPEN and Food and Drugs Administration - FDA
[7,11,22]. Samples were withdrawn aseptically from each
mixture at appropriate intervals.
A total volume of 100 mL of each formulation was
prepared. For each bag, the theoretical weight was calcu-
lated, taking into account the densities of each solution
used. After preparation, each bag was weighed and a ±
5% variation was regarded as acceptable [22].
Sterility assessment
Sterility was assessed by determining the growth of
microorganisms in the admixtures. Thus, 5 mL of each
TPN were inoculated in flasks containing 4 mL of sterile
Trypticase Soy and sterile Trypticase Soy Agar, solidified
in the bent position (TSA/TSB). Samples were incubated
at 37°C ± 3°C for 14 days, as described by Ribeiro and
colleagues [3].
Physicochemical stability evaluation
All analyses were performed at 0, 24 h, 48 h, 72 h and
7 days after the preparation of the admixtures. The first
analysis, time 0, was undertaken at approximately
45 minutes (t0 ~ 45 min) after the preparation was made,
taking into account the time of sample transportation to
the laboratory of analysis. Each TPN admixture was
incubated at three different temperatures: 5°C ± 3°C in a
refrigerator, to simulate storage conditions, 25°C ± 3°C,
room temperature and 40°C ± 3°C, to simulate body
temperature. The study was performed with three differ-
ent lots of each TPN admixture tested (n = 3).
Visual inspection of the emulsion status was per-
formed using the criteria of phase separation and color
alteration at 0, 24 h, 48 h, 72 h and 7 days after the
preparation of the admixtures, following ASPEN recom-
mendations and a method previously described [3,11].
Digital photographs of the TPN bags were taken at the
appropriate time periods and any alterations were docu-
mented. The height of the cream layer formed was mea-
sured with a 15 cm paquimeter. Before the sampling
procedure to the physicochemical analyses, the TPN
bags were submitted to a gently agitation in order to
guarantee the homogenization.
Theoretical osmolarities of the three admixtures
(mOsm/L H2Ot) were calculated based on the concen-
trations of the nutrients added and on the osmolarities
described for the solutions used to prepare the TPN.
The osmolalities were experimentally confirmed using
an Osmette Freezing Point Osmometer (2430 Multi-
Osmette, Natick, MA, USA) by the freezing pointdetermination. The osmolality (mOsm/Kg H2Oexp) was
converted to osmolarity (mOsm/L H2O), using the dens-
ity of the TPN admixtures measured using a picnometer.
The average density obtained was 1.04 at 25°C. The ex-
perimental osmolarity of the TPN admixtures was esti-
mated by multiplying the osmolality value obtained by
the density of TPNs, subtracted from the concentration
of the nutrients in each TPN (0.2 g/L) as described by
Martin in 1993 [24].
The pH of the three formulations studied was deter-
mined in triplicate for all time points (0, 24, 48, 72 h
and 7 days) and at all temperatures studied (5°C, 25°C
and 40°C), using a pH meter/conductimeter (Mettler-
Toledo, MPC 227, Schwerzenbach, Zurich, Switzerland),
calibrated with buffer solutions pH 4.0 and 7.0 (Merck
KgaA, Darmstadt, Germany). Samples of 10 mL were
collected from each bag for each measurement taken.
The pH determination was made by direct immersion
of the electrode in the emulsion, at room temperature
(25°C).
Zeta potential was determined by microelectrophoresis
using a Zetasizer 3000 Hs (Malvern Instruments, Wor-
cestershire, United Kingdom). Samples were injected
with 5 mL syringes into the microelectrophoretic cell
which was subsequently washed five times with water
for injection (WFI; USP) between each measurement.
Analyses were made in triplicate, using TPN prepared
on different days. A similar sample preparation method
as described in DLS analysis below was used for deter-
mination of zeta potential.
To determine peroxide levels, 5 mL samples of TPN
preparations were transferred into 125 mL Erlenmeyer
flasks. Then, 30 mL of acetic acid:chloroform (3:2) was
added while stirring to dissolve the sample. Thereafter,
0.5 mL of saturated solutions (1.4 g/ml) of potassium
iodide was added and the solutions were stored in a dark
place for one minute. Next, a 1% starch solution was
added as a colorimetric indicator that confirmed oxida-
tion of iodide to iodine. The iodine that was formed was
titrated with 0.01 N thiosulphate volumetric solution.
Globule size determination
Lipid physical stability was assessed by optical micros-
copy (OM) and dynamic light scattering (DLS), as
described below. The percentage of fat globules (PFATx)
was estimated by light obscuration (LO). The determina-
tions followed the same protocol (time and storage tem-
peratures) used in the physicochemical assessments.
Optical microscopy (OM)
To determine the size and microscopic characteristics of
the lipid globules, the TPN emulsions studied, were eval-
uated with an optical microscope Axoplan 2 (Carl Zeiss,
Jena, Germany) and then switched to a photo camera
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many), a computer and a TV monitor. An amplification
of 100x was used for imaging (Pan Neofluar, Carl Zeiss)
with a numeric opening of 1.30 and / / 0.17. The dilu-
ent used was the same admixture of TPN without the
addition of lipids. Many dilutions were tested in order to
obtain optimal microscopy photographs that allowed
counting of the lipid globules. After the sample was
diluted 5X, an aliquot of 5 μL was dispersed over the
lamina. Use of a small volume reduced the amount of
Brownian motion within the emulsions and assisted in
obtaining clear photographs for posterior analysis.
The OM images were treated using the software Ana-
lySIS (Soft Imaging System, Münster, Germany), that
transformed the images obtained into a binary system,
so that the particles could be counted and their dia-
meters measured. Approximately, 1000 particles for each
field were used for the counts
Dynamic light scattering (DLS)
The samples, 1 mL, were collected from the TPN bags,
under laminar flow hood, in a clean room, with sterile
syringes and needles and appropriately diluted with fil-
tered WFI (0.2 μM) 1:500 to obtain the Kcps (a measure
of the sample concentration, obtained by the equipment)
from 250 to 350. Each analysis was performed in tripli-
cate, using TPN prepared on different days. DLS mea-
surements were carried out using a Zetasizer 3000Hs
(Malvern Instruments, Worcestershire, United Kingdom),
which uses a helium-neon laser light and an integrated
analysis software. The temperature was adjusted to 25°C
and the scattering angle was set to 90°, in the DLS
equipment, before measurements were taken. The chosen
data analysis method was the monomodal or cumulant
analysis [25]. The data were expressed as z-average and
polydispersity.
Light obscuration (LO)
We followed the methodology previously described
[17,26,27]. Analysis were performed using the previously
calibrated PAMAS Particle Counter equipment (model
SVSS, PAMAS GmbH, Sttutgart, Germany), utilizing a
sensor HCB-LD-50/50, in extinction mode and software
according to CFR 21 part 11. On each day of analysis,
1 mL samples were collected from the TPN bags with
sterile syringes and needles and appropriately diluted
with WFI 1:200. Next, the diluted samples were trans-
ferred to flasks containing magnetic stir bars for analysis.
The diameters selected for the analysis were 2.0, 5.0, 7.5,
10, 15, 20, 25 and 30 μm; the flow rate was 10 mL/min
and the volume accuracy was ± 0.4 %. The calculation of
PFATx was based on previous descriptions [27,28]. Par-
ticle sizes were grouped with their respective counts.
Data were transferred from PAMAS SVSS software toMicrosoft Excel for calculation of PFATx (X= 2, 5 and
10 μm) and each specified diameter was converted on a
volume basis [27].
Statistical analysis
Continuous variables were expressed as mean ± SD.
Data obtained by physical and physicochemical assess-
ments were analyzed by paired t tests of dependent
groups for all TPN and by one way ANOVA. Statistical
tools of GraphPadW Prism were used in data analysis.
Graphical representations were plotted in Microsoft
ExcelW and in GraphPad PrismW.
Results and discussion
Sterility maintenance and osmolarity evaluation of TPN
Microbial contamination was not detected in any of the
formulations under investigation even after storage for
seven days at 40 ± 3°C. This test confirmed that sterility
of the formulations was maintained and that compound-
ing was adequate, thus ensuring that the results were
not altered due to microbial contamination.
Theoretical osmolarity was calculated for the formula-
tions and found to be 875 mOsm/L H2O. This value was
experimentally confirmed by measuring osmolality for
each admixture (mOsm/Kg of H2O): 1029 ± 29 for NP1;
1009 ± 14 for NP2; and 1020 ± 32 for NP3. Osmolality
was then converted into osmolarity, giving the following
values: 864 mOsm/L, for NP1; 845 mOsm/L, for NP2;
and 857 mOsm/L, for NP3. It is crucially important to
determine osmolarity, as it will define the access of the
infusion – central or peripheral – and also whether it is
possible to prepare the formulation according to the
prescribed concentrations. The osmolarities deter-
mined for NP1, NP2 and NP3 comply with the recom-
mendations of ASPEN, which correspond to values below
1200 mOsm/L for central infusion in pediatric patients
[7,11].
Visual inspection and peroxide formation in TPN
Visual inspection of a parenteral admixture, which can
be a transparent solution or an opaque emulsion, is
mainly limited by human visual accuracy. Despite its
limitations, visual observation is essential, since it is one
of the methods routinely applied for quality assurance of
parenteral admixtures and can be used to detect physical
signs of instability [9,16,22,23].
Visual alterations that were observed in NP1, NP2 and
NP3 admixtures during the sample period were analyzed
and presented in Table 2. Each TPN bag that was stored
at a different temperature was individually analyzed.
During inspection of phase separation, special care was
taken to prevent agitation of the bags to avoid
homogenization before observations were recorded,
which would lead to an erroneous conclusion. Color
Table 2 Visual inspection of NP1, NP2 and NP3 admixtures
Admixtures NP1 NP2 NP3
Time T(°C) Colora Phaseseparation Colora Phaseseparation Colora PhaseSeparation
0 h 5 N/A no N/A no N/A no
25 N/A no N/A no N/A no
40 N/A no N/A no N/A no
24 h 5 N/A no N/A no N/A no
25 A no A no A no
40 A no A no A no
48 h 5 N/A no N/A no N/A no
25 A 0.1 cm C A 0.1 cm C A 0.1 cm C
40 A 0.1 cm C A 0.1 cm C A 0.1 cm C
72 h 5 N/A no N/A no N/A no
25 A 0.2 cm C A 0.2 cm C A 0.2 cm C
40 A 0.2 cm C A 0.2 cm C A 0.2 cm C
7 days 5 N/A no N/A no N/A no
25 A 0.2 cm C A 0.2 cm C A 0.2 cm C
40 A 0.2 cm C A 0.2 cm C A 0.2 cm C
a N/A =not altered; A = altered; C = creaming.
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from the initial color.
The initial stage in emulsion breakdown is creaming,
which occurs almost immediately upon mixing of the fat
emulsion with other chemical constituents, such as elec-
trolytes or vitamins. The presence of a cream layer is
visible as an opaque white layer separated from the
remaining TPN admixture at the surface of the emul-
sion. Although the lipid particles in the cream layer are
destabilized, the individual droplet identities are gener-
ally preserved. An emulsion with a cream layer is an
expected consequence of this pharmaceutical formula-
tion and is generally safe for patient administration since
it is reversible [26,27].
Visual inspection indicated that slight creaming, readily
reversible with gentle agitation, was evident after 48 h of
TPN storage at 25°C and 40°C. Considering that the size
of the lipid particles remained unaltered during the
study, the formation of a cream layer did not affect the
micro-structure of the TPN admixtures. It is important
to note that at the indicated storage temperature (2°C to
8°C) none of the admixtures presented a cream layer dur-
ing the stability study. These results are in accordance
with those of Driscoll and colleagues [12] and Lee and
colleagues [20], although neither of them evaluated
pediatric admixtures, which contain higher relative nutri-
ent concentrations and smaller final volumes than adult
admixtures.
Regarding the alteration of color, darkening of the
emulsion was observed in the first 24 h of the admix-
tures stored at 25°C and 40°C. Darkening was observedup to 72 h and did not progress further after this time
point. Differences in the visual aspects between the three
studied formulations were not detected. The color alter-
ation may be due to Maillard reaction or to vitamin
degradation, however this was not an aim of this study
[29]. Color alterations did not affect droplet size mea-
sured either by OM or DLS, neither PFAT5.
Peroxide formation was not detected in any of the
studied TPN, using iodimetric titration after 72 h, nei-
ther for those formulations maintained at 40°C or those
which presented darkening or cream layer formation.
pH evaluation
The pH of all the TPN studied (NP1, NP2 and NP3) was
at the recommended range, around 5.5 at time zero [13].
After 72 hours, pH variation was less than 0.1 for all
conditions. Even the NP3 admixture, which could be
prone to incompatibility due to a possible interaction be-
tween vitamins and trace elements, did not have any
variation in pH value.
It has already been demonstrated that macronutrient
concentrations can alter the stability of TPN admixtures
[9,10,30,31]. Very low amino acid concentrations can re-
sult in a less stable emulsion, due to a decreased buffer-
ing effect, which would directly affect the final pH of
TPN admixtures. Final pH values lower than 5.0 have
been shown to be destabilizing [12,20,26,31]. The com-
mercial intravenous lipid emulsions for use in TPN
admixtures have a standard pH range between 6.0 and
9.0, which keep the negative net charge of the lipid glo-
bules [13].
Figure 1 Zeta potential mean variation in NP3, during 7 days of study, at 4°C (black bars), 25°C (light gray bars) and 37°C (dark gray
bars) (n = 3; mean± SD; P> 0.05, between 0 and 7 days).
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The means for the NP3 zeta potential for each storage
condition are shown in Figure 1. Although slight oscilla-
tions were observed at 5°C, 25°C and 40°C during the
seven days of study, the results are statistically similar as
shown by Student’s t test (p> 0.05), for each storage
time with respect to time zero. The same pattern was
observed for NP1 and NP2. As expected, the zeta poten-
tial values, which depend directly on pH, were unaltered,
since they were maintained at the recommended range
for emulsion stability, between −30 and −50 mV [16,32].
The net surface electrical charge, translated by zeta
potential, has been extensively studied previously
[16,33,34], nevertheless it has been receiving less atten-
tion in recent years. Assessing the zeta potential is crit-
ical for quality assurance of TPN formulations, since it
translates the efficacy of the emulsifier [35].
Globule size determination by DLS, OM and LO
Table 3 summarizes the medium diameters of globules
obtained by OM (Figure 2), the Z-average and the poli-
dispersity obtained by DLS and the PFAT5 (%) deter-
mined by LO for NP1, NP2 and NP3, stored at three
different temperatures, and time points of 0, 48 h and
7 days.
Analysis of DLS values in triplicate gave statistically
similar results after application of t test (p> 0.05), taking
time 0 as reference, and the polidispersity index was less
than 0.3 for all samples, as presented in Table 3, showing
homogeneity of the dispersions.
The instrument used for particle size distribution ana-
lysis capable of detecting a wide range of lipid globule
diameters from 1 nm to 3 μm [36]. The results obtainedby DLS in this study showed that there was no alteration
in the lipid globules diameter at any time or storage
temperature employed in this study [37].
The DLS results are in agreement with USP 31 <729
>which points out that the mean droplet diameter size
obtained by light scattering methods must be less than
500 nm for lipid injectable emulsions [14,37]. Addition-
ally, the values obtained in this study are similar to those
reported by Driscoll and colleagues who used DLS to
analyze 34 different parenteral nutrition formulations
after compounding, at time 0 and 30 h, the particle
diameter varied ± 10 nm [38].
DLS is an efficient, qualitative method that demon-
strates the homogeneity of an emulsion, but it fails to
quantify different globule diameters that are distant from
the mean. In view of this, the USP recommends a sec-
ond method, LO, to determine the extent of large-diam-
eter droplet tail (> 5 μm) [13,14,18]. This method, also
called Light Extinction (LE) employs a technique named
single-particle optical sizing (SPOS) and is based on the
effect produced by a particle as it crosses a beam of laser
light. When the particle (in this case, a globule) crosses
a beam of light in the sensing zone, it produces a type of
shadow. This causes a voltage pulse in the photodetector,
which is converted to particle size. The photodetector is
calibrated with polystyrene latex microspheres (PSL) of
known size and the voltage pulse that is generated is
converted into spherical diameter optical equivalent [39].
LO has been widely studied by some authors in recent
years, especially by Driscoll [1,12,13,16,37,38,40] who has
been researching intravenous lipid emulsions and paren-
teral nutrition admixtures for a extended time. Further-
more, LO is recommended by the USP to quantify the
Table 3 Lipid particles diameter sizes calculated OM, DLS and LO (PFAT5), in NP1, NP2 and NP3
Time T (°C) OMa (nm) DLS PFAT5 (%)
z-average (nm) PDI
NP1
0 h 25 810 ± 270 275 ± 24 0.091 0.05 ± 2  10-3
48 h 5 870 ± 111 269 ± 16 0.085 0.05 ± 1  10-3
25 400 ± 250 275 ± 10 0.105 0.03 ± 1  10-3
40 800 ± 360 270 ± 01 0.065 0.02 ± 2  10-3
7 days 5 750 ± 250 271 ± 09 0.065 0.04 ± 1  10-3
25 560 ± 170 274 ± 08 0.045 0.03 ± 1  10-3
40 480 ± 370 272 ± 11 0.055 0.04 ± 1  10-3
NP2
0 h 25 760 ± 320 280 ± 12 0.035 0.02 ± 1  10-3
48 h 5 950 ± 450 268 ± 30 0.050 0.02 ± 4  10-4
25 810 ± 320 267 ± 27 0.065 0.02 ± 6  10-4
40 630 ± 240 262 ± 21 0.055 0.01 ± 5  10-4
7 days 5 620 ± 180 257 ± 14 0.045 0.02 ± 8  10-4
25 650 ± 240 274 ± 02 0.035 0.01 ± 4  10-4
40 540 ± 190 264 ± 14 0.105 0.01 ± 3  10-4
NP3
0 h 25 580 ± 190 272 ± 06 0.053 0.05 ± 1  10-3
48 h 5 600 ± 180 279 ± 14 0.065 0.05 ± 8  10-4
25 650 ± 240 272 ± 05 0.075 0.05 ± 6  10-4
40 880 ± 450 274 ± 04 0.065 0.05 ± 5  10-4
7 days 5 520 ± 170 272 ± 06 0.065 0.04 ± 9  10-4
25 610 ± 190 268 ± 13 0.060 0.05 ± 1  10-3
40 640 ± 210 270 ± 07 0.065 0.05 ± 1  10-3
number of determinations = 3; results are presented as average ± SD. amedium droplet size.
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percentage of fat residing in globules larger than 5 μm -
PFAT5 [14,27,41]. USP Chapter <729> recommends that,
to be considered stable, an intravenous lipid emulsions
must present PFAT5 less than 0.05% [14]. Globules higher
than 5 μm can obstruct the lungs, causing emboli, other
complications and even death [14,42]. As shown in
Table 3, after statistical analysis by one way ANOVA and
by t test and Wilcoxon test, results show that, for all stor-
age times and at all temperatures studied, none of the for-
mulations presented a PFAT5> 0.05%. Although there
were significant differences between NP1 versus NP2 and
NP2 versus NP3, none of the formulations exceeded the
limit of 0.05% for PFAT5, established by USP. There were
no significant changes observed between NP1 and NP3.
The preparation that had the lowest % of PFAT5 was NP2,
this result may be related to the absence of vitamins in
this formulation. The PFAT5 results presented in this
work are similar to those obtained by Driscoll and collea-
gues in 2003, when studying the stability of different lipid
emulsions for PN admixtures. In that study it was foundout that MCT/LCT emulsions added to PN formulations
led to more stable admixtures [1,40,43,44]. In addition,
PFAT5 results corroborate the other results of DLS and
OM that will be presented below.
In order to make a comparison, beyond PFAT5, the
percentage of fat globules were calculated to be 2 μm
and 10 μm. Figure 3 presents these percentages for NP3
and confirms that PFAT5, did not show significant
changes, however PFAT2 and PFAT10 also remained un-
changed as well, These results confirmed that the glob-
ule size pattern was maintained at all temperatures
studied during the 7 days of storage. In addition, PFAT2
and PFAT10 were calculated for the formulations NP1
and NP2 and followed the same pattern as shown in
Figure 3.
Furthermore, OM was particularly useful for imaging
the PN formulations. This technique is a valuable
method for the detection of larger droplets and to detect
early flocculation in PN formulations [45,46]. However,
the size distributions or a medium droplet size in col-
loidal formulations are not so reliable. For this purpose
Figure 2 Representative photomicrography of NP3 after 72 h
of storage.
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sents poor statistics for PN analysis, as previously
demonstrated [13], due the lack of repeatability and ac-
curacy that can be evidenced by the Table 3. As can be
observed in Table 3 the medium droplet size obtained
by the DLS and OM methods are divergent. However,
both methods are complementary and demonstrate the
stability of the formulations, as there were not found
globules larger than 4 μm in all temperatures tested
(Table 4).
Although, the use of this technique is nowadays easier
due to the availability of modern image analyzing soft-
ware it possesses a major limitation, even presenting a
detection limit of approximately 0.2 μm, it is usual to
see a diffraction halo around the particle which can leadFigure 3 Relation among PFAT2, PFAT5 e PFAT10 for NP3, maintainedto gross overestimation of its size [39]. Another signifi-
cant limitation of this technique is that it is restricted to
observation of samples as a whole and is influenced by
the sample field observed (Figure 2). The USP indicates
OM, in addition to light obscuration, to determine par-
ticulate matter in injections [1,13,14,19,22]. Microscope
examination is a useful method for measurement of par-
ticles from 3 μm to 1 mm and is the only method avail-
able to observe and measure individual particles,
moreover it is a useful low-cost stability control method
and can be easily used is a pharmacy-based compound-
ing unit [39,46]. This can be very interesting in countries
such as Brazil, where frequently compounding units can-
not invest a large amount of money in equipments.
Table 3 shows the medium diameter values of lipid
globules, found in photomicrographs, obtained after ana-
lysis of three representative fields for each of the formu-
lations NP1, NP2 and NP3 at times 0, 48 h and 7 days,
at all of the studied temperatures. The results obtained
for 24 h and 72 h are not shown, but presented the same
pattern. Subsequently, results are statistically similar
after application of the parametric t test (p> 0.05), using
time 0 as reference. Even when the overestimation gen-
erally associated with this approach is considered, OM
analysis confirmed what had already been observed by
DLS analysis. The TPN formulations were stable with re-
gard to droplet sizes and homogeneity of dispersion, for
every time point and temperature studied. Furthermore,
the globules mean diameters were within similar ranges.
This pattern was similar to the other formulations, as
Driscoll and colleagues previously demonstrated using
electron microscopy. They showed that three formula-
tions for pediatric parenteral nutrition, which had a lipid
phase MCT/LCT of 20%, maintained the microstructureat 5°C ± 3°C (2°C - 8°C), during seven days of study.
Table 4 Maximum diameter obtained by OM for NP1, NP2
and NP3 when storage at 25°C (μm)
Time of storage NP1 NP2 NP3
0 h 2.66 2.88 1.97
48 h 2.88 3.82 3.01
7 days 1.97 2.15 1.98
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[1].
The OM software allowed other parameters, apart
from the diameters, to be obtained, such as globule
shape, tendency toward sphericity and Ferret diameter.
These parameters were not altered for all the formula-
tions, under the different storage conditions, tested in
this study.
The results obtained in this study indicate that all the
formulations were stable under the studied conditions,
with regard to lipid globule size and homogeneity of the
dispersions and the concomitant presence or absence of
trace elements and vitamins within the formulations.
Notwithstanding, although differences were found in
lipid globule diameters, by DLS and by OM, the values
were confirmed to be lower than 1 μm by either
method tested. Globules measured by OM displayed a
medium diameter around 600 nm, while mean diam-
eter sizes obtained by DLS appeared to be around
300 nm. Analysis of images obtained by OM using the
software AnalySIS leads to overestimation, as seen
above, of globule diameter sizes during conversion to a
binary system when a shadow appears around the glo-
bules. Because of this OM is only useful when accom-
panied by and compared to measurements obtained by
other methods.
Optical microscopy allowed characterization of glo-
bules of higher diameter, which appeared in photomicro-
graphs. Globules were detected in the range of 2 μm,
3 μm, 5 μm and even 10 μm. However, no more than
0.05% of the globules were found with diameter sizes
over 5 μm, suggesting that the formulations were stable
[1,15,19,20,37,40]. Lewis, in 1993, justified the use of a
1.2 μm line filter for total nutrient admixture infusion
showing that catheter’s occlusion by TPN 3 in 1 emulsion
is higher than by 2 in 1 emulsions. Additionally other
groups, including ASPEN and FDA, demonstrated that
catheter’s occlusion was significantly higher in patients
that received 3 in 1 TPN therapy, in contrast to those who
separately received the lipid emulsion [1,5-7,14,47-49].
No significant differences were found between the for-
mulations in this study. The presence of trace elements
and vitamins in the same neonatal formulation, which
has a reduced final volume, did not affect the stability
parameters evaluated in this study. Color alterations and
cream layer formation (reversible) were only noted forthe formulations that were stored at 25°C and 37°C.
Thus, storage conditions with a temperature between 2°
C and 8°C recommended by Brazilian and international
guidelines, preserve all the initial characteristics of the
admixtures for storage up to 7 days [2,24].
Both DLS and OM are useful methods for the analysis
of lipid droplet size in 3 in 1 emulsions of TNP. How-
ever, they are complementary procedures to analyze par-
ticles of different size ranges. DLS is apparently able to
characterize homogeneity of the dispersion and OM, on
the other hand, allows visualization of the emulsion with
enhanced droplet sizes [50].
According to ASPEN (1998) it is recommended that
decisions related to stability and compatibility should be
made according to the most reliable information avail-
able from the literature or manufacturer of intravenous
nutrients. ASPEN recommends that PN formulations
should be inspected for signs of gross particulate, con-
tamination and/or phase separation. However, there is
no mandatory legislation that obligates pharmacists re-
sponsible for compounding TPN to perform physico-
chemical analysis [11].
Although USP 31 [14] indicates only LO and Light
Scattering Methods, as DLS, to determine lipid intraven-
ous emulsion stability it also indicates optical micros-
copy (OM) for determination of particulate matter in
injections [51]. Additionally, British Pharmacopoeia and
European Pharmacopoeia indicates both LO and OM, for
sub-visible particulate matter determination [13,16,52,53].
DLS and OM appear to be more accessible, considering
that most publications recommend that these methods
should be applied for quality assurance of TPN formula-
tions and/or lipid injectable emulsions. Visual inspection,
pH determination and zeta potential constitute comple-
mentary methods, although they do not always yield
conclusive information [19,20,44,48,54].
Conclusions
In spite of changes in physical appearance, concomitant
presence of trace elements and vitamins in the same neo-
natal formulation (NP3) did not alter any aspects of stabil-
ity that were evaluated: pH, peroxide levels, zeta potential,
globule size distribution and PFAT5, which remained un-
altered and in accordance to the limits indicated by the lit-
erature. Although changes in physical appearance (color
alteration and cream layer formation) were observed,
these alterations were not found when the formulations
were stored at 2°C and 8°C. Under these conditions, all of
the initial characteristics were preserved, even after 7 days.
Nevertheless, to ensure the chemical stability of the for-
mulations, a more detailed study is necessary to assess the
darkening of preparations and vitamin concentrations,
along a time course and over a wide range of temperatures
[3,4,8,10,31,48,55].
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the use of 1.2 μm in-line filters is reinforced (to prevent
administration of particulate matter to patients. In-line
filtration of TPN admixtures has been internationally
indicated since the “1994, FDA Safety Alert”. Despite
this, the use of these filters may be limited in some
countries due the high cost, though its use should be
mandatory [23].
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